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Is it Time to Reconsider?*Joshua M. Hare, MD,yzx Cristina Sanina, MDyC linical trials of autologous bone marrowmononuclear cells (BMMC) for acute myo-cardial infarction (AMI) have faced many
challenges, but this therapeutic concept has pro-
gressed to phase III clinical trials. Two major related
approaches, intracoronary injection of whole BMMCs
and granulocyte colony-stimulating factor (G-CSF)
administration to mobilize BMMCs, continue to be
tested in humans but have produced controversialSEE PAGE 2372results (1,2). In this issue of the Journal, San Roman
et al. (3) present the results of the TECAM trial (Trial
of Hematopoietic Stem Cells in Acute Myocardial
Infarction), which evaluated the efﬁcacy of both ther-
apeutic approaches alone or in combination in the
setting of AMI and successful percutaneous coronary
intervention (PCI). The TECAM trial did not meet its
primary endpoint and is thus a negative trial. It is
valuable to review the trial’s results and place them
in the context of earlier similar studies that examined
the efﬁcacy of intracoronary autologous BMMCs and
G-CSF therapy for AMI.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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paper to disclose.In the TECAM trial, investigators performed a
randomized, single-blinded, multicenter, open-label,
controlled phase II clinical trial investigating the
effects of autologous intracoronary BMMCs and
G-CSF administration in combination and separately
in the setting of successfully perfused ST-segment
elevation myocardial infarction via PCI with drug-
eluting stents. The trial, conducted in Spain from
2005 to 2010, enrolled patients (n ¼ 120) with AMI
who were randomized and assigned on the second day
post-PCI to 4 groups: 1) intracoronary BMMC injection;
2) subcutaneous G-CSF injections; 3) both G-CSF
and BMMC injections; and 4) conventional treatment
(PCI only). All treatments were performed within
5 days following PCI. The primary endpoints included
absolute change in 12-month left ventricular ejection
fraction (LVEF) and LV end-systolic volume assessed
by cardiac magnetic resonance imaging and left
ventriculography. Secondary endpoints evaluated
changes in LV end-diastolic volume, infarct size,
infarct area (infarct size/LV myocardial mass),
segmental contractility, and clinical events. As ex-
pected, G-CSF treatment resulted in aw7-fold increase
in the number of BMMCs isolated from bone marrow
aspirate. Therefore, group 3 (G-CSF and BMMCs)
received intracoronary injection of 560  106 cells
versus group 1 (BMMCs only), which received 83  106
cells. None of the active treatments signiﬁcantly
improved either LVEF or LV end-systolic volume at
1 year. Despite this, infarct area was signiﬁcantly
reduced by 5  7 percentage points in both BMMC
and/or G-CSF treated groups. Thus, although not
meeting its primary endpoint, the study revealed an
interesting secondary endpoint of infarct size reduc-
tion, a ﬁnding now seen consistently in trials of cell
therapy for chronic ischemic cardiomyopathy (4,5).
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2384BMMC-AMI TRIALS 2002 TO 2015
A key challenge in regenerative medical treatment for
AMI is the shifting landscape of the disease. Impor-
tantly, the case fatality rate of acute ST-segment eleva-
tion myocardial infarction has fallen dramatically
by 24.2% in the last 3 decades caused in large part
by aggressive reperfusion therapy (6). Randomized
trials have collectively demonstrated reduced mor-
tality, improved event-free survival, and fewerBMMC and G-CSF AMI Trials (2002–2015)
Trial (Ref. #) Year
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al. (28) 2007 24/14 39
15) 2008 80/40 59
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te myocardial infarction; ASTAMI ¼ Autologous Stem cell Transplantation in Acute Myocard
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mary PCI (7,8).
Nevertheless, preventing coronary artery disease
progression and development of post-MI heart fail-
ure remains a major challenge. Therefore, multiple
randomized and nonrandomized (9) studies have
investigated the potential role and efﬁcacy of BMMC or
G-CSF therapy for AMI in conjunction with PCI or
thrombolysis. Most of these trials chose global LVEF as
a primary endpoint but failed to show any signiﬁcantMC Group
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FIGURE 1 LVEF in Bone Marrow Mononuclear Cell and
Granulocyte Colony-Stimulating Factor Trials
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Left ventricular ejection fraction (LVEF) improved in two-thirds of trials studied before
2009, but none after that (A). Overall, there was not a tremendous amount of variance in
mean baseline LVEF and LVEF increase in bone marrow mononuclear cell or granulocyte
colony-stimulating factor trials (B). Trial abbreviations as in Table 1.
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2385changes in LVEF compared with control subjects
(Table 1, Figure 1A). Interestingly, the results of
earlier trials (2002 to 2008), which were smaller and
less likely to include randomization and blinding,
were optimistic. Later trials (2009 to present), which
were larger and adequately controlled, have been
disappointing.
EJECTION FRACTION AS PRIMARY ENDPOINT
Trials of bone marrow therapy for AMI have tended to
choose EF over infarct size as the primary endpoint.
Because of improving reperfusion strategies over the
past 15 years, it has been increasingly difﬁcult to enroll
populations with markedly depressed EF. In this re-
gard, mean baseline LVEF among enrolled patients in
TECAM was only modestly depressed atw45% (Table 1,
Figure 1B), a range associated with low cardiac-related
event rates (10), which might leave little room for
improvement. Various BMMC trials performed in 2002
through 2010 (9,11–18) demonstrated LVEF improve-
ment that varied from 1.9% to 8.5% and were pre-
dominantly not signiﬁcantly different (Table 1,
Figure 1B). Interestingly, trials that have enrolled pa-
tients with lower EF have shown beneﬁt from cell
therapy (11,12). We cannot disregard the fact that a few
trials (13,14) showed a signiﬁcant infarct size reduction,
whereas almost all investigators described a nonsig-
niﬁcant reverse cardiac remodeling in cell-treated
groups.
Meta-analyses of BMMC trials for AMI demon-
strated that intracoronary cell therapy signiﬁcantly
decreases infarct size (19) and overall improves LVEF
by 2.99% (20). The review of most G-CSF trials did not
show any beneﬁcial effects in moderate (<45%) or
severe (<35%) LV dysfunction (Table 1), suggesting
that G-CSF therapy is unlikely to improve LV recovery
in patients with AMI post-reperfusion (21). Thus, in
this context, the TECAM trial reinforces the conclu-
sions of previous studies and meta-analyses that
G-CSF and/or BMMC therapies do not produce sig-
niﬁcant clinical beneﬁts in global LV function
recovery.
IMPACT ON INFARCT SIZE
Many studies of both AMI and chronic ischemic car-
diomyopathy reveal that cell therapy reduced infarct
size. Given the availability of imaging techniques,
such as cardiac magnetic resonance imaging, which
can measure infarct size (4,5), reduction in MI size
and improvement in ventricular remodeling repre-
sent potentially important surrogate endpoints for
trials of regenerative medicine strategies.FUTURE DIRECTIONS
Given the experience fromBMMCandG-CSF trials, future
cell-based studies for AMI should be unambiguously
larger, controlled, and randomized. The current standard
of care for AMI, the 90-min or less door-to-balloon time, is
widely available in developed countries, resulting in
improved in-hospital and long-term survival (22). As
such, adjunctive cell/growth factor therapy for patients
who have had PCI and have EFs $45% may be less im-
pactful than in patients with more severe persistent LV
dysfunction, as may occur in patients who do not receive
PCI. Importantly, LVEF is not a clinically relevant primary
endpoint, such as mortality, hospitalizations, or major
adverse cardiac events (23). Because of its limitations,
LVEF is best used as a selection criteria or secondary
endpoint for future cell-based studies.
With regard to methods of cell delivery, intra-
venous, intracoronary, and intramyocardial cell
administration already have been tested and proven
safe in AMI and chronic heart failure (5,24,25). Cur-
rent studies are investigating the therapeutic poten-
tial of other cell types and growth factors for AMI. The
concept of “off the shelf” cell delivery post-AMI with
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is becoming more attractive and convenient because
of immediate cell availability (24). Finally, the new
large-scale BAMI trial (NCT01569178), with a target
enrollment of 3,000 patients, will provide more
conclusive answers as to the clinical efﬁcacy of BMMC
infusions for patient survival in AMI.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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